Sarcoidosis. Typical and atypical thoracic manifestations and complications

Freundlich, Irwin M.; Libshitz, Herman I.; Glassman, Leonard M.; Israel, Harold L.

doi:10.1016/s0009-9260(70)80072-1

Cited by 83 publications

(28 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This complication has been reported in ,3% of all sarcoid patients in retrospective series [25,26]. In a prospective study, aspergilloma, as documented by the finding of serum precipitins or by chest radiograph and/or tomography, occurred in 31.2% of patients with stage III/IV disease (both categories were merged) during a 10-yr period [27].…”

Section: Discussionmentioning

confidence: 99%

Stage IV sarcoidosis: comparison of survival with the general population and causes of death

Nardi

Py²,

Letoumelin³

et al. 2011

Eur Respir J

217

158

View full text Add to dashboard Cite

The objectives of this study were to compare the survival of sarcoid patients with pulmonary fibrosis with that of the general population and to determine the causes of death and the incidence of evolutive complications.This retrospective cohort included 142 sarcoid patients in radiographic stage IV (74 males; mean¡SD age 48.1¡12 yrs). Their survival was compared with that of the general French population, matched for the year and age at diagnosis of stage IV disease, sex and length of follow-up. Expected survival probabilities were calculated year-by-year on the basis of probabilities provided by official demographic data for France. Survival curves were based on the Kaplan-Meier method and compared using the log-rank test.During the follow-up period (7.1¡4.8 yrs), pulmonary hypertension (PH) was observed in 29.7% of cases and aspergilloma in 11.3%. Long-term oxygen therapy was required in 12%. Survival was 84.1% at 10 yrs, which was worse than for the general population (p50.013). 16 (11.3%) patients died from the following causes: refractory PH (n55), chronic respiratory insufficiency (n54), acute respiratory insufficiency (n52), haemoptysis due to aspergilloma (n51), heart sarcoidosis (n51), nocardiosis (n51) and unknown causes (n52).Survival is significantly decreased in stage IV patients. 75% of fatalities are directly attributable to respiratory causes.

show abstract

Section: Discussionmentioning

confidence: 99%

Stage IV sarcoidosis: comparison of survival with the general population and causes of death

Nardi

Py²,

Letoumelin³

et al. 2011

Eur Respir J

217

158

View full text Add to dashboard Cite

show abstract

“…In US studies up to 1984, cavitation rates varied from 2% to 12.5% and aspergilloma rates from 1% to 11% [29][30][31][32][33][34][35][36]. In later studies from Israel, Turkey and France, aspergilloma rates varied from 0% to 2.1% [1,37,38].…”

Section: Cpa Complicating Sarcoidosismentioning

confidence: 99%

Global burden of chronic pulmonary aspergillosis complicating sarcoidosis

Pleuvry²,

2012

View full text Add to dashboard Cite

Chronic pulmonary aspergillosis (CPA) may complicate pulmonary sarcoidosis. We re-estimated the global burden of sarcoidosis and the burden of CPA complicating sarcoidosis.We searched the literature and reference lists of retrieved papers to identify all published sarcoidosis incidence and prevalence data. We estimated the frequency of CPA from 11 papers relating to .3,000 patients with sarcoidosis to derive CPA patient numbers. We applied an annual attrition rate of 15% (range 10-25%) to estimate the global burden of CPA.We estimate that the annual incidence of sarcoidosis is 344,000 patients worldwide and the prevalence is ,1,238,000 cases, distributed as follows: 165,979 in Europe, 224,000 in the Americas, 492,892 in Africa, 80,023 in the Eastern Mediterranean, 41,660 in the West Pacific and 234,010 in Southeast Asia. CPA complicates sarcoidosis in 3-12% of cases. Using a 6% frequency, we estimate a global burden of 71,907 (range 35,954-143,815 (3-12%)) CPA cases complicating sarcoidosis, with 24% and 37% of cases estimated to be present in the Americas and Africa, because of the higher incidence of sarcoidosis in black people.As CPA responds to long-term antifungal therapy, which may prevent life-threatening haemoptysis, screening periodically for CPA in those with pulmonary sarcoidosis may be important, especially in patients requiring corticosteroid therapy.

show abstract

“…Cavitary lesions can be seen in all the stages of sarcoidosis, but are most common in stage III and IV disease, with a reported prevalence on chest radiography of 0.6-1.3% and on CT image of 2.2% [68][69][70]. Most cavitary lesions do not resolve, but spontaneous resolution has been reported in about 10-25% of patients [70].…”

Section: Parenchymal Complications Cavities and Mycetomasmentioning

confidence: 99%

Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation

Shlobin¹,

Nathan²

2012

Eur Respir J

View full text Add to dashboard Cite

Sarcoidosis is not only a multisystem, but also a multinational disease that is prevalent throughout the world, including Europe, the USA and Japan. Lung involvement in sarcoidosis is seemingly invariable, with up to 95% of patients manifesting some form of pulmonary disease during the course of their lifetime. The natural history of sarcoidosis in the lung is quite variable and spans the spectrum from spontaneous resolution to advanced fibrocystic disease in ,5% of cases. Advanced sarcoidosis will be the subject of this review with a special focus on pulmonary hypertension and lung transplantation as a last-resort treatment option for some patients with end-stage disease.

show abstract

Sarcoidosis. Typical and atypical thoracic manifestations and complications

Cited by 83 publications

References 11 publications

Stage IV sarcoidosis: comparison of survival with the general population and causes of death

Stage IV sarcoidosis: comparison of survival with the general population and causes of death

Global burden of chronic pulmonary aspergillosis complicating sarcoidosis

Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation

Contact Info

Product

Resources

About